Tivic Health Systems, Inc. - TIVC STOCK NEWS

Tivic Health Systems, Inc. (Nasdaq: TIVC) is set to report its financial results for the year ending December 31, 2022, through a pre-recorded conference call and webcast scheduled for March 31, 2023, at 1:30 PM PT / 4:30 PM ET. Shareholders are encouraged to submit questions by March 27, 2023, at 5:00 PM ET. Tivic Health specializes in non-invasive bioelectronic treatments aimed at addressing inflammation and related conditions. The company emphasizes its commitment to enhancing consumer choices in healthcare. Interested parties can access the webcast at the provided link.

Tivic Health Systems (TIVC), a health technology company specializing in bioelectronic medicine, announced the completion of supplier qualification and first article inspection with ALOM, enhancing production efficiency. This advancement aims to decrease third-party logistics costs by up to 30% and reduce assembly costs by 40% per unit. This move is part of Tivic's strategy to improve margins and cost management, confirming that their production processes meet regulatory standards.

Tivic Health Systems, Inc. (TIVC) has completed an underwritten public offering, issuing 20,000,000 shares of common stock at $0.25 each, raising approximately $5 million. The underwriters also have a 45-day option for an additional 3,000,000 shares. The funds will primarily support the expansion of their ClearUP® product for sinus relief and cover clinical and regulatory expenses for future products. While Tivic is exploring potential strategic investments, no definitive agreements are currently in place. The registration statement for this offering was effective as of February 8, 2023, with the prospectus filed on February 10, 2023.

Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, announced a public offering of 20 million shares at $0.25 each, aiming for approximately $5 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 3 million shares. Proceeds will be used for expanding sales of its product ClearUP® for sinus relief and for clinical and regulatory costs related to new product candidates. The offering is expected to close on February 13, 2023, subject to standard conditions.

Tivic Health Systems, Inc. (TIVC), recognized as the Most Pioneering Bioelectronic Medicine Company of 2022 by Global Health & Pharma, emphasizes the growing field of bioelectronic medicine. CEO Jennifer Ernst highlighted the shift from traditional drug therapeutics to innovative electronic solutions for chronic conditions. The company's ClearUP device, a non-invasive treatment for sinus pain, has earned accolades as the Most Innovative Sinus Relief Solution for two consecutive years. Tivic Health's commitment to evidence-based, non-invasive therapies positions it as a leader in the evolving healthcare landscape.

Tivic Health Systems (Nasdaq: TIVC) has mutually terminated its agreement with Reliefband Technologies regarding the acquisition of the Reliefband product line, initially announced on October 7, 2022. CEO Jennifer Ernst cited volatile capital market conditions as a primary reason for this decision. Despite the setback, the relationship between the two companies remains positive, and Tivic is focused on accelerating sales of its ClearUP product while exploring other growth opportunities.

Tivic Health Systems (TIVC) has hired ALOM Technologies Corporation to enhance its supply chain management, aiming for cost improvements and scalable growth in the bioelectronic medicine sector. ALOM will manage inventory, logistics, and fulfillment from its 19 global locations. This partnership follows a recent agreement with Microart Services Inc. to significantly reduce manufacturing costs by 70% for certain components. Tivic has also increased the MSRP for its ClearUP products by $20 to improve margins.